Journals / Turkish Journal of Gastroenterology / 2015 / Cilt: 26 - Sayı: 1

Association between polymorphism of dopamine D2 receptor genes and therapeutic effect of domperidone in functional dyspepsia

Pages
1–5
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The therapeutic effect of domperidone in these patients was associated with polymorphism of dopamine D2 receptor TaqI gene.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Functional dyspepsia (FD) is a common gastrointestinal disease, for which domperidone is one of the most commonly used drugs.
📊
Key Findings & Data:Single nucleotide polymorphism (SNP) of the dopamine D2 receptor genes 141C Ins/Del, A-241G, and TaqI, were analyzed by ligase detection reaction.
💡
Conclusion & Impact:The therapeutic effect of domperidone in these patients was associated with polymorphism of dopamine D2 receptor TaqI gene.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Functional dyspepsia (FD) is a common gastrointestinal disease, for which domperidone is one of the most commonly used drugs. This study aimed to investigate the potential causes of the varying therapeutic effects of domperidone among FD patients. Materials and Methods: The effects of domperidone therapy in patients with FD were evaluated using a clinical symptom score combined with real-time ultrasonography examination of antral motor index. Single nucleotide polymorphism (SNP) of the dopamine D2 receptor genes 141C Ins/Del, A-241G, and TaqI, were analyzed by ligase detection reaction. Results: The results of real-time ultrasonography correlated with clinical symptom scores. Single nucleotide polymorphism analysis of dopamine D2 receptor TaqI gene showed that the genotype frequencies of C/C , C/T , and T/T in the effective group were 51.35%, 31.08%, and 17.57%, respectively; the allele frequencies were 66.89% and 33.11%. In the ineffective group, the genotype frequencies of C/C , C/T , and T/T were 17.81%, 52.05%, and 30.14%, respectively; and the allele frequencies were 43.84% and 56.16%. The difference was statistically different between the two groups (p<0.01). Conclusion: Clinical symptom scores combined with real-time ultrasonography is effective in evaluating the therapeutic effect of domperidone in patients with functional dyspepsia. The therapeutic effect of domperidone in these patients was associated with polymorphism of dopamine D2 receptor TaqI gene.

🔖

Cite This Article

XİANG, Z., MA, H., MOU, Y., FU, C. X. (2015). Association between polymorphism of dopamine D2 receptor genes and therapeutic effect of domperidone in functional dyspepsia. Turkish Journal of Gastroenterology, Cilt: 26 - Sayı: 1, 1–5. https://ajindex.com/articles/410244

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239-55. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
  2. Caldarella MP, Azpiroz F, Malagelada JR. Antro-fundic dysfunctions in functional dyspepsia. Gastroenterology 2003; 124: 1220-9.
  3. Mizuta Y, Shikuwa S, Isomoto H, et al. Recent insights into digestive motility in functional dyspepsia. J. Gastroenterol 2006; 41: 1025-40.
  4. Talley NJ, Locke GR, Lahr BD, et al. Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut 2006; 55: 933-9.
  5. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroentero 2001; 96: 689-96.
  6. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007; 102: 2036-45.
  7. Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol 2006; 41: 513-23.
  8. Szarka LA, Camilleri M. Gastric emptying. Clin Gastroenterol Hepatol 2009; 7: 823-7.
  9. El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004; 19: 643-54.
  10. Fischler B, Tack J, De Gucht V, et al. Heterogeneity of symptom pattern, psychosocial factors, and pathophysiological mechanisms in severe functional dyspepsia. Gastroenterology 2003; 124: 903-10.
  11. Metugriachuk Y, Marotta F, Kuroi O, et al. Effect of a phyto-compound on delayed gastric emptying in functional dyspepsia: a randomized-controlled study. J Dig Dis 2008; 9: 204-7. Serra J. Levosulpiride in the management of functional dyspepsia and delayed gastric emptying. Gastroenterol Hepatol 2010; 33: 586-90.
  12. Bolondi L, Bortolotti M, Santi V, Calletti T, Gaiani S, Labò G. Measurement of gastric emptying time by real-time ultrasonography. Gastroenterology 1985; 89: 752-9.
  13. Darwiche G, Almer LO, Bjorgell O, Cederholm C, Nilsson P. Measurement of gastric emptying by standardized real-time ultrasonography in healthy subjects and diabetic patients. J Ultrasound Med 1999; 18: 673-82.
  14. Marzio L, Giacobbe A, Conoscitore P, Facciorusso D, Frusciante V, Modoni S. Evaluation of the use of ultrasonography in the study of liquid gastric emptying. Am J Gastroenterol 1989; 84: 496-500.
  15. Parkman HP, Jacobs MR, Mishra A